About Cutaneous Lymphoma

The Cutaneous Lymphoma Foundation Launches Research Awards Program

Thu, 01/31/2013

BIRMINGHAM, MI, January 31, 2013 – The Cutaneous Lymphoma Foundation (CLF) announced today the roll-out of their CLARIONS grant program to fund cutaneous lymphoma research.  CLARIONS stands for Curing Cutaneous Lymphoma by Advancing Research, Innovation and Offering New Solutions.  

“The launch of our CLARIONS grant program is a clear demonstration that the CLF is achieving its goal of facilitating research toward a cure for cutaneous lymphoma,” said Susan Thornton, CEO, Cutaneous Lymphoma Foundation.  “CLF is extremely grateful for the significant support we receive from our benefactors which makes these grants possible.  

The Cutaneous Lymphoma Foundation CLARIONS grant program supports investigators interested in conducting innovative cutaneous lymphoma research. The grants will help uncover causes and improve the treatment and quality of life for patients. Discovering new avenues for better therapies today and, one day, a cure for cutaneous lymphoma, are goals of this program.

The CLARIONS grant program seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest in:

  • Etiology and risk factors of cutaneous lymphomas.
  • Measures of disease impact on individuals and populations affected by cutaneous lymphomas.
  • Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.
  • Optimizing therapies for cutaneous lymphomas.
  • Improving quality of life for individuals with cutaneous lymphomas.

CLARIONS Grant Calendar

  • January 31- Public announcement of Request for Application (RFA)
  • July 31 - Application Deadline
  • August – October, – Grant review by scientific board
  • November – Recipients notified of award
  • December - Grant awards announced at ASH meeting
  • January - Disbursement of Award and beginning of new award cycle

“The Cutaneous Lymphoma Foundation is proud to be a driving force behind researchers who are working tirelessly to find a cure for cutaneous lymphoma,” said Pierluigi Porcu, MD, Associate Professor of Medicine Division of Hematology, Comprehensive Cancer Center, The Ohio State University, CLF Board Member.  “The CLARIONS grant strengthens our commitment to these researchers and distinguishes the CLF as a global leader in cutaneous lymphoma research,” stated Stuart Lessin, MD, CLF Board President.

The Scientific Review Board (SRB) is chaired by Thomas S. Kupper, MD, Chairman, Department of Dermatology, Brigham and Women’s Hospital, Disease Center Leader, Cutaneous Oncology, Thomas B. Fitzpatrick Professor of Dermatology, Harvard Medical school.  Dr. Kupper is joined by several esteemed members of the cutaneous lymphoma clinical community.  The SRB will evaluate each application using criteria that includes scientific merit of the proposal, investigator track record, institutional environment and impact of the proposal on the mission of the CLF.

Investigators at all levels, from clinical and post-doctoral fellows to established investigators, are eligible to receive awards.

For more information on cutaneous lymphoma, the Cutaneous Lymphoma Foundation and the CLARIONS grant program, please visit www.clfoundation.org/research/research-awards-program.

About Cutaneous Lymphomas
Cutaneous lymphomas are cancers of lymphocytes (white blood cells) that primarily involve the skin. Classification is based on lymphocyte type: B-lymphocytes (B-cell) or T-lymphocytes (T-cell).  Cutaneous T-cell lymphoma (CTCL) is the most common type of cutaneous lymphoma that typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement is variable and may be accompanied by tumor formation, ulceration and exfoliation, complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood, and internal organs.

Cutaneous lymphomas affect thousands of individuals worldwide. CTCL affects over 30,000 in the United States and Canada. The incidence of CTCL is increasing in the US with approximately 3,000 new cases being diagnosed annually.

About the Cutaneous Lymphoma Foundation
The Cutaneous Lymphoma Foundation is an independent, nonprofit patient advocacy organization whose mission is to support every person with cutaneous lymphoma by promoting awareness and education, advancing patient care, and facilitating research. The Cutaneous Lymphoma Foundation was founded in 1998 and it is the only organization worldwide that offers comprehensive programs and services that provide information, resources and support to people affected by cutaneous lymphoma.  The Cutaneous Lymphoma Foundation currently serves people from 67 countries who access our organization for assistance and support.  For more information, please visit www.clfoundation.org or contact the Foundation at (248) 644-9014 or .